BioWorld

May 23, 2011

Biotech Launches Disappoint: Why and Lessons Learned

Over the past two years, a handful of biotech companies have achieved the ultimate goal: launching their own products and transitioning from clinical to commercial enterprises. Read More

'Never Say Never' May Apply to Curing HIV

Biotech Stocks Hold Steady As ASCO Releases Abstracts

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

Biotechnology Company Deals With Other Biotechnology Companies: Apr. 1 - May 20, 2011

Top 10 Deals Between Biotech Companies: 2011

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: Apr. 1 - May 20, 2011

Biotech–Biotech Collaborations: Modified Agreements: Apr. 1 - May 20, 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...